These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 1379160)
1. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Grant SM; Goa KL Drugs; 1992 Jun; 43(6):889-924. PubMed ID: 1379160 [TBL] [Abstract][Full Text] [Related]
2. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148 [TBL] [Abstract][Full Text] [Related]
3. [The role of iloprost in the treatment of critical ischemia of the limbs]. Poggesi L; Comeglio M Ann Ital Med Int; 1993 Oct; 8 Suppl():71S-77S. PubMed ID: 7509614 [TBL] [Abstract][Full Text] [Related]
4. Possibilities for clinical use of prostacyclin in vascular disease. Poredos P Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643 [TBL] [Abstract][Full Text] [Related]
5. Possibilities for clinical use of prostacyclin in vascular disease. Poredoš P Pflugers Arch; 2000 Jan; 440(Suppl 1):R137-R138. PubMed ID: 28008512 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. Hildebrand M Eur J Clin Pharmacol; 1997; 53(1):51-6. PubMed ID: 9349930 [TBL] [Abstract][Full Text] [Related]
7. The influence of iloprost on blood rheology and tissue perfusion in patients with intermittent claudication. Ciuffetti G; Sokola E; Lombardini R; Pasqualini L; Pirro M; Mannarino E Kardiol Pol; 2003 Sep; 59(9):197-204. PubMed ID: 14618196 [TBL] [Abstract][Full Text] [Related]
8. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III. Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study. Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734 [TBL] [Abstract][Full Text] [Related]
10. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170 [TBL] [Abstract][Full Text] [Related]
11. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. Balzer K; Bechara G; Bisler H; Clevert HD; Diehm C; Heisig G; Held K; Mahfoud Y; Mörl H; Rücker G Int Angiol; 1991; 10(4):229-32. PubMed ID: 1724669 [TBL] [Abstract][Full Text] [Related]
12. [Use of a synthetic prostacyclin in extracorporeal circulation]. Massonnet-Castel S; Farge D; Tournay D; Dubois D; Fabiani JN; Terrier-Mouilleron E; Carpentier A Presse Med; 1992 Jan; 21(3):113-8. PubMed ID: 1372124 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia. Goulielmos NV; Enayat ZE; Sheridan DJ; Cohen H; Flores NA Cardiovasc Res; 1995 Nov; 30(5):788-98. PubMed ID: 8595628 [TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455 [TBL] [Abstract][Full Text] [Related]
15. Myocardial ischemia induced by prostacyclin and iloprost. Bugiardini R; Galvani M; Ferrini D; Gridelli C; Tollemeto D; Mari L; Puddu P; Lenzi S Clin Pharmacol Ther; 1985 Jul; 38(1):101-8. PubMed ID: 2408809 [TBL] [Abstract][Full Text] [Related]
16. [Iloprost (Ilomedine) and extracorporeal circulation with conventional heparinization in a patient with heparin-induced thrombocytopenia]. Corbeau JJ; Jacob JP; Moreau X; Cottineau C; De Brux JL; Delhumeau A Ann Fr Anesth Reanim; 1993; 12(1):55-9. PubMed ID: 7687835 [TBL] [Abstract][Full Text] [Related]
17. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis]. Cordioli E; Virgilio S; Ghirardi R; Martinelli M Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297 [TBL] [Abstract][Full Text] [Related]
18. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Blardi P; de Lalla A; Pieragalli D; De Franco V; Meini S; Ceccatelli L; Auteri A Prostaglandins Other Lipid Mediat; 2006 Sep; 80(3-4):175-82. PubMed ID: 16939882 [TBL] [Abstract][Full Text] [Related]
19. Thromboangiitis obliterans: a rare cause of a reversible Raynaud's phenomenon. Noël B; Krayenbühl B; Cerottini JP; Guggisberg D; Buxtorf K; Pires A; Panizzon RG Dermatology; 2000; 200(4):363-5. PubMed ID: 10894979 [TBL] [Abstract][Full Text] [Related]
20. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Fiessinger JN; Schäfer M Lancet; 1990 Mar; 335(8689):555-7. PubMed ID: 1689791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]